학술논문
292P Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
Document Type
Abstract
Author
Source
In Annals of Oncology September 2021 32 Supplement 5:S492-S492
Subject
Language
ISSN
0923-7534